The expression levels of full-length MYO1B transcript (MYO1B-fl) and full-length protein in drug-resistant BC cell lines were significantly decreased after CYT treatment, while SRSF1 overexpression could restore its levels. This evidence concerns the gene MYO1B and breast cancer.